Data were collected from the Glanzmann’s Thrombasthenia Registry (GTR), the Hemostasis and Thrombosis Research Society (HTRS) registry, and the published literature. The GTR was observational, and therefore not designed to select doses. The GTR captured data for 218 Glanzmann’s thrombasthenia patients with 1073 bleeding and surgical events. An independent adjudication committee assessed clinical refractoriness and antibody status based upon historical data from investigators, patterns of treatment, and treatment responses when only platelets were used. Adjudicators defined clinical refractoriness as lack of platelet response. Patients with apparent response to platelets only were not considered refractory, even if coded as such by investigators. Antibody status included GPIIb/IIIa, HLA, and unspecified platelet-specific antibodies. Efficacy was evaluated on a two-point scale (clinical assessment of success or failure of treatment regimen as a whole, blinded and unblinded to investigator coded outcome) in 190 patients with 755 episodes requiring systemic hemostatic therapy (151 patients with 564 severe bleeding episodes, 90 patients with 192 surgeries, one episode was classified as both). Of these a total of 92 patients were treated with NOVOSEVEN RT for 266 bleeding episodes and 77 patients treated for 160 surgical procedures. A large number of bleeding episodes were treated with NOVOSEVEN RT alone (109/266 (41%) events).
The median dose of NOVOSEVEN RT administered for bleeding episodes and surgical procedures was 90 micrograms per kg and the median interval between doses was 3 hours.
For all subjects, concomitant use of other hemostatic agents occurred in 157/266 (59%) bleeding episodes and 94/160 (59%) surgical procedures.
The majority of NOVOSEVEN RT treated bleeding episodes were in pediatric patients (65%; children and adolescents, 0-16 yrs.).
Of the 266 bleeding episodes treated with NOVOSEVEN RT, the most common types of bleeding episodes were: epistaxis (116, 43.6%), gum bleeding (48, 18.0%), menorrhagia (36, 13.5%), tooth/dental extraction related (29, 10.9%), and gastrointestinal (23, 8.6%).
Of the patients treated with NOVOSEVEN RT for surgical procedures, 86% were adults (> 16 years). Major surgery was defined as any invasive operative procedure in which, body cavity was entered, mesenchymal barrier was crossed, facial plane was opened, organ was removed or normal anatomy was operatively altered. Minor surgery was defined as any invasive operative procedure in which only skin, mucous membranes, or superficial connective tissue were manipulated. Surgical procedures treated with NOVOSEVEN RT included minor (134/160; 83.8%) and major (26/160, 16.3%) procedures. Dental procedures were most common (106, 66.3%), followed by endoscopy (12, 7.5%), nasal procedures (8, 5.0%), excision (7, 4.4%), GI surgery (7, 4.4%) and orthopedic procedures (6, 3.8%). Most surgeries were elective (147, 91.9%), with a few emergency (7, 4.4%) or unspecified (6).
Overall, treatment with NOVOSEVEN RT was successful in 94.4% of bleeding episodes (Table 9) and 99.4% of surgical procedures (Table 10). Adjudicator-rated efficacy was consistent across treatment regimens, bleed and surgery types, age, and refractory/antibody status. Treatment with NOVOSEVEN RT was successful in patients with clinical refractoriness with or without platelet-specific antibodies in 94.9% of bleeding episodes and 98.6% of surgical procedures. In patients without refractoriness or platelet-specific antibodies, treatment with NOVOSEVEN RT was comparable to treatment with platelets.
Table 9: Adjudicator Evaluation of Efficacy – Bleeding Episodes for GTR Data
| No. of patientsc | No. of episodes | Success | Failure | Insufficient data | No Consensus | |
All NOVOSEVEN* | 92 | 266 | 251 (94.4) | 4 (1.5) | 6 (2.3) | 5 (1.9) | |
By Treatment Regimen | |
NOVOSEVEN only | 44 | 109 | 101 (92.7) | 2 (1.8) | 4 (3.7) | 2 (1.8) | |
NOVOSEVEN ± Platelets ± Other hemostatic agents | 69 | 157 | 150 (95.5) | 2 (1.3) | 2 (1.3) | 3 (1.9) | |
By Antibody/Refractory Group | |
Refractoriness ± Platelet-specific antibodiesa,d | 31 | 79 | 75 (94.9) | 2 (2.5) | 2 (2.5) | 0 (0.0) | |
Platelet-specific-antibodiesa,d | 8 | 10 | 10 (100.0) | 0 (0.0) | 0 (0.0) | NA | |
Neither or unknownb,d | 57 | 177 | 166 (93.8) | 2 (1.1) | 4 (2.3) | 5 (2.8) | |
*All treatment regimens that included treatment with NOVOSEVEN
a includes GPIIb/IIIa, HLA, and unspecified platelet-specific antibodies
b Assumes no platelet-specific antibodies or refractoriness reported or antibody and refractory status unknown
c Patient numbers are not additive. Patients may have episodes with different treatment regimens and have more than one antibody/refractory status
d Treatment was NOVOSEVEN only for 26/79 episodes with refractoriness with or without antibodies, 2/10 episodes with platelet specific antibodies only, and 81/177 episodes with neither or unknown. The remainder received NOVOSEVEN with platelets and/or antifibrinolytic agents.
Table 10: Adjudicator Evaluation of Efficacy – Surgical Procedures for GTR Data
Treatment group | No. of patientsc | No. of procedures | Success | Insufficient datad |
All NOVOSEVEN* | 77 | 160 | 159 (99.4) | 1 (0.6) |
By Treatment Regimen |
NOVOSEVEN only | 35 | 66 | 65 (98.5) | 1 (1.5) |
NOVOSEVEN ± Platelets ± Other hemostatic agents | 57 | 94 | 94 (100.0) | 0 (0.0) |
By Antibody/Refractory Group |
Refractoriness ± Platelet-specific antibodiesa,e | 33 | 70 | 69 (98.6) | |
Platelet-specific antibodiesa,e | 11 | 24 | 24 (100.0) | |
Neither or unknownb,e | 36 | 66 | 66 (100) | |
*All treatment regimens that included treatment with NOVOSEVEN
a includes GPIIb/IIIa, HLA, and unspecified platelet-specific antibodies
b Assumes no platelet-specific antibodies or refractoriness reported or antibody and refractory status unknown
c Patient numbers are not additive. Patients may have episodes with different treatment regimens and have more than one antibody/refractory status
d No reports of failure or lack of consensus was reported
e Treatment was NOVOSEVEN only for 22/70 episodes with refractoriness with or without antibodies, 13/24 episodes with platelet specific antibodies only, and 31/66 episodes with neither or unknown. The remainder received NOVOSEVEN with platelets and/or antifibrinolytic agents.
In HTRS, there were 7 patients that were treated with NOVOSEVEN RT for 23 bleeding episodes. Concomitant hemostatic agents were administered for 11 episodes (antifibrinolytics in 10 episodes). Treatment was reported effective in 21 of 23 (91.3%) episodes. In the other 2 episodes, bleeding was reported as slowed or no improvement, however in neither episode was further treatment reported. There were no surgical procedures reported in the HTRS registry.